Home LiteratureArticle Details
PMID: 2460637 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing).

Journal of virology ·Vol. 62 ·No. 12 ·1988-12-00 ·Pages 4594-604

Virgin HW, Bassel-Duby R, Fields BN, Tyler KL

Abstract

The mammalian reoviruses have provided a valuable model for studying the pathogenesis of viral infections of the central nervous system (CNS). We have used this model to study the effect of antibody on disease produced by the neurally spreading reovirus type 3 (Dearing) (T3). Polyclonal and monoclonal antibodies protect mice from fatal infection with T3 after either footpad or intracerebral virus challenge. Protection occurs with monoclonal antibodies directed against the viral cell attachment protein sigma 1, and with polyclonal antisera without T3 sigma 1 binding activity. In vivo protection occurs with both neutralizing and nonneutralizing monoclonal antibodies. Antibody-mediated protection does not require serum complement and, under specific circumstances, can occur via Fc-independent mechanisms. Antibody can protect mice when transferred up to 5 days after intracerebral challenge and up to 7 days after footpad challenge, times when high titers of virus are present in the CNS. Thus, antibody mediated protection against this neurally spreading virus does not require neutralizing antibody or serum complement and occurs even in the face of established CNS infection.

MeSH Terms
Animals Antibodies, Monoclonal/immunology Antibodies, Viral/immunology Brain/microbiology Capsid Proteins Cross Reactions Epitopes/immunology Hemagglutination Inhibition Tests Immunization, Passive Immunoglobulin G/immunology Mammalian orthoreovirus 3/immunology Mice Neutralization Tests Precipitin Tests Radioimmunoassay Reoviridae/immunology Reoviridae Infections/prevention & control Viral Proteins/immunology
Chemicals
Antibodies, Monoclonal Antibodies, Viral Capsid Proteins Epitopes Immunoglobulin G Viral Proteins sigma 1 protein, reovirus
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Virgin H W
Department of Microbiology & Molecular Genetics, Harvard Medical School, Boston, Massachusetts.
Bassel-Duby R
Fields B N
Tyler K L
References (70)
70 references, click to expand
  1. Alterations in expression of measles virus polypeptides by antibody: molecular events in antibody-induced antigenic modulation.
    J Immunol. 1980 Jul;125(1):78-85 PMID: 7381212
  2. Isolation of the anticomplementary protein from cobra venom and its mode of action on C3.
    J Immunol. 1971 Dec;107(6):1666-72 PMID: 5120401
  3. Reovirus type 3 encephalitis: observations of virus-cell interactions in neural tissues. II. Electron microscopic studies.
    Lab Invest. 1971 Feb;24(2):101-9 PMID: 5542731
  4. The role of antibody in recovery from experimental rabies. I. Effect of depletion of B and T cells.
    J Immunol. 1978 Jul;121(1):321-6 PMID: 307577
  5. Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions.
    J Immunol. 1970 Jul;105(1):55-69 PMID: 4246566
  6. Immune complex effects on murine macrophages. I. Immune complexes suppress interferon-gamma induction of Ia expression.
    J Immunol. 1985 Dec;135(6):3735-43 PMID: 3934266
  7. Passive immune protection by herpes simplex virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicity.
    J Virol. 1985 Dec;56(3):930-7 PMID: 2415719
  8. Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies.
    J Virol. 1985 Sep;55(3):594-600 PMID: 2410632
  9. Sigma 1 protein of mammalian reoviruses extends from the surfaces of viral particles.
    J Virol. 1988 Jan;62(1):246-56 PMID: 3275434
  10. Evidence for functional domains on the reovirus type 3 hemagglutinin.
    Virology. 1982 Feb;117(1):146-55 PMID: 6175082
  11. Molecular basis of reovirus neurovirulence: role of the M2 gene in avirulence.
    Proc Natl Acad Sci U S A. 1982 Feb;79(4):1298-302 PMID: 6951176
  12. Pathogenesis of viral infections. Basic concepts derived from the reovirus model.
    N Engl J Med. 1985 Feb 21;312(8):486-97 PMID: 2982096
  13. Suppression of immune response to Listeria monocytogenes: mechanism(s) of immune complex suppression.
    Infect Immun. 1985 Nov;50(2):343-53 PMID: 3932204
  14. Breakdown of the blood--cerebrospinal fluid barrier to immunoglobulin in mice injected intracerebrally with a neurotropic influenza A virus. Post-exposure treatment with monoclonal antibody promotes recovery.
    J Neuroimmunol. 1981 Sep;1(3):227-37 PMID: 7334080
  15. Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis.
    J Virol. 1985 Mar;53(3):727-34 PMID: 3973964
  16. Murine hepatitis virus-4 (strain JHM)-induced neurologic disease is modulated in vivo by monoclonal antibody.
    Virology. 1984 Jan 30;132(2):261-70 PMID: 6199889
  17. Induction of subacute murine measles encephalitis by monoclonal antibody to virus haemagglutinin.
    Nature. 1981 Apr 16;290(5807):588-9 PMID: 6783963
  18. Retrograde transport and differential accumulation of serum proteins in motor neurons: implications for motor neuron diseases.
    Neurology. 1987 May;37(5):843-6 PMID: 2437495
  19. Expression of reovirus type 3 (Dearing) sigma 1 and sigma s polypeptides in Escherichia coli.
    J Gen Virol. 1987 Jan;68 ( Pt 1):135-45 PMID: 3543215
  20. Monoclonal antibodies against the fusion protein are protective in necrotizing mumps meningoencephalitis.
    J Virol. 1986 Apr;58(1):220-2 PMID: 3754016
  21. Alternative pathway for the activation of complement in human serum. Formation and composition of the complex with cobra venom factor that cleaves the third component of complement.
    Hoppe Seylers Z Physiol Chem. 1974 Feb;355(2):171-83 PMID: 4215726
  22. Neutralization of reovirus: the gene responsible for the neutralization antigen.
    J Exp Med. 1977 Nov 1;146(5):1305-10 PMID: 925604
  23. Antibody-mediated recovery from subcutaneous herpes simplex virus type 2 infection.
    Infect Immun. 1978 Aug;21(2):489-95 PMID: 689732
  24. Polypeptide components of virions, top component and cores of reovirus type 3.
    Virology. 1969 Dec;39(4):791-810 PMID: 4311639
  25. Intraneuronal IgG in the central nervous system: uptake by retrograde axonal transport.
    Neurology. 1987 Nov;37(11):1780-4 PMID: 2444904
  26. Mechanisms of neutralization of animal viruses.
    J Gen Virol. 1984 Jun;65 ( Pt 6):1015-22 PMID: 6202836
  27. Correlation between epitopes on hemagglutinin of measles virus and biological activities: passive protection by monoclonal antibodies is related to their hemagglutination inhibiting activity.
    Virology. 1985 Jul 15;144(1):46-58 PMID: 2414919
  28. Uptake of reovirus serotype 1 by the lungs from the bloodstream is mediated by the viral hemagglutinin.
    J Virol. 1988 Feb;62(2):545-51 PMID: 3336070
  29. Ocular infection with herpes simplex virus type 1: prevention of acute herpetic encephalitis by systemic administration of virus-specific antibody.
    J Infect Dis. 1979 Oct;140(4):534-40 PMID: 229174
  30. A study on serotherapy of poliomyelitis in rhesus monkeys.
    Br J Exp Pathol. 1959 Apr;40(2):133-44 PMID: 13638495
  31. Pathogenesis of herpes simplex virus in congenitally athymic mice: the relative roles of cell-mediated and humoral immunity.
    J Gen Virol. 1982 Jun;60(Pt 2):225-33 PMID: 6286849
  32. Antiviral antibody reacting on the plasma membrane alters measles virus expression inside the cell.
    Nature. 1979 Jun 7;279(5713):529-30 PMID: 450095
  33. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses.
    J Gen Virol. 1986 Feb;67 ( Pt 2):229-34 PMID: 3944585
  34. Neutralizing antibodies to visna lentivirus: mechanism of action and possible role in virus persistence.
    J Virol. 1986 Jul;59(1):37-44 PMID: 3012120
  35. Distinct pathways of viral spread in the host determined by reovirus S1 gene segment.
    Science. 1986 Aug 15;233(4765):770-4 PMID: 3016895
  36. Mechanisms of monoclonal antibody-mediated protection against virulent Semliki Forest virus.
    J Virol. 1985 May;54(2):546-51 PMID: 2985817
  37. Use of monoclonal antibodies for analysis of antibody-dependent immunity to ocular herpes simplex virus type 1 infection.
    Infect Immun. 1982 Oct;38(1):168-74 PMID: 6292092
  38. Monoclonal antibody cure and prophylaxis of lethal Sindbis virus encephalitis in mice.
    J Virol. 1986 Apr;58(1):107-15 PMID: 2419592
  39. Experimental poliomyelitis following intramuscular virus injection. II. Viremia and the effect of antibody.
    Bull Johns Hopkins Hosp. 1961 May;108:320-33 PMID: 13727931
  40. Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice.
    J Gen Virol. 1986 Mar;67 ( Pt 3):591-5 PMID: 3950582
  41. Suppression of the immune response to Listeria monocytogenes. I. Immune complexes inhibit resistance.
    J Immunol. 1984 Jul;133(1):104-9 PMID: 6202779
  42. Molecular basis of viral neurotropism: experimental reovirus infection.
    Neurology. 1985 Jan;35(1):88-92 PMID: 2981418
  43. The cobra venom factor-dependent C3 convertase of human complement. A kinetic and thermodynamic analysis of a protease acting on its natural high molecular weight substrate.
    J Biol Chem. 1982 Jul 25;257(14):8292-9 PMID: 6919543
  44. Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48.
    J Immunol. 1985 Oct;135(4):2805-9 PMID: 4031501
  45. Role of Fc fragments in antibody-mediated recovery from ocular and subcutaneous herpes simplex virus infections.
    Infect Immun. 1981 Jul;33(1):109-14 PMID: 6266961
  46. Inhibitory effects of passive antibody on virulent poliovirus excretion and on immune response in chimpanzees.
    Bull Johns Hopkins Hosp. 1960 Sep;107:143-62 PMID: 13801930
  47. Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease.
    Infect Immun. 1981 Oct;34(1):192-9 PMID: 6271681
  48. The effect of complement depletion on the course of Sindbis virus infection in mice.
    J Immunol. 1978 Oct;121(4):1276-8 PMID: 701795
  49. Elucidation of the topography and determination of the protective epitopes on the E glycoprotein of Saint Louis encephalitis virus by passive transfer with monoclonal antibodies.
    J Immunol. 1984 Mar;132(3):1533-7 PMID: 6198396
  50. Immunotherapy of murine leukemia. IX. The requirement for the Fc portion of antibody for successful passive serum therapy of Friend leukemia virus-induced disease.
    Virology. 1983 Apr 15;126(1):259-66 PMID: 6573816
  51. Absolute linkage of virulence and central nervous system cell tropism of reoviruses to viral hemagglutinin.
    J Infect Dis. 1980 May;141(5):609-16 PMID: 6989930
  52. A new mechanism for the neutralization of enveloped viruses by antiviral antibody.
    Nature. 1986 May 15-21;321(6067):244-6 PMID: 3713806
  53. THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY.
    Biochem J. 1963 Oct;89:114-23 PMID: 14097352
  54. Host defenses in herpes simplex infections of the nervous system: effect of antibody on disease and viral spread.
    Infect Immun. 1979 Feb;23(2):305-11 PMID: 217828
  55. Protective monoclonal antibodies define maturational and pH-dependent antigenic changes in Sindbis virus E1 glycoprotein.
    Virology. 1983 Oct 15;130(1):144-54 PMID: 6195815
  56. Role of the immune response in recovery from Sindbis virus encephalitis in mice.
    J Immunol. 1977 Mar;118(3):1070-5 PMID: 845432
  57. MURINE INFECTION WITH REOVIRUS: I. PATHOLOGY OF THE ACUTE PHASE.
    Br J Exp Pathol. 1963 Aug;44:427-36 PMID: 14079016
  58. The interaction of a series of hybridoma IgGs with reovirus particles. Demonstration that the core protein lambda 2 is exposed on the particle surface.
    Virology. 1981 Jan 15;108(1):147-55 PMID: 7269234
  59. A study of the effect of antiserum on poliovirus infection induced by the intraspinal inoculation of rhesus monkeys.
    J Immunol. 1958 Feb;80(2):106-13 PMID: 13514079
  60. Study of protein characteristics that influence entry into the cerebrospinal fluid of normal mice and mice with encephalitis.
    J Clin Invest. 1982 Aug;70(2):289-95 PMID: 7096568
  61. Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3).
    J Immunol. 1973 Jan;110(1):128-38 PMID: 4734384
  62. Protective effect of monoclonal antibodies on lethal mouse hepatitis virus infection in mice.
    J Virol. 1986 Jul;59(1):168-71 PMID: 3012115
  63. Cyclophosphamide-potentiated West Nile viral encephalitis: relative influence of cellular and humoral factors.
    J Infect Dis. 1974 Dec;130(6):634-41 PMID: 4372273
  64. Experimental studies on passive immunization against poliomyelitis. II. The prophylactic effect of human gamma globulin on paralytic poliomyelitis in cynomolgus monkeys after virus feeding.
    Am J Hyg. 1952 Jul;56(1):78-89 PMID: 14933392
  65. Topographical analysis of epitope relationships on the envelope glycoprotein of yellow fever 17D vaccine and the wild type Asibi parent virus.
    Virology. 1986 Apr 30;150(2):333-41 PMID: 2421479
  66. Molecular basis of reovirus virulence: role of the S1 gene.
    Proc Natl Acad Sci U S A. 1977 Dec;74(12):5744-8 PMID: 271999
  67. Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis.
    Nature. 1982 May 6;297(5861):70-2 PMID: 6280072
  68. Experimental poliomyelitis following intramuscular virus injection. III. The effect of passive antibody on paralysis and viremia.
    Bull Johns Hopkins Hosp. 1962 Oct;111:198-220 PMID: 13937699
  69. Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2.
    Infect Immun. 1982 Sep;37(3):1132-7 PMID: 6290390
  70. IgG-mediated viral clearance in experimental infection with herpes simplex virus type 1: role for neutralization and Fc-dependent functions but not C' cytolysis and C5 chemotaxis.
    J Infect Dis. 1985 Mar;151(3):464-70 PMID: 2982965
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
DOI
10.1128/JVI.62.12.4594-4604.1988
Published
1988-12-00
Pages
4594-604
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC253571
Subset
IM
Grants
NINDS NIH HHS · 2 P50 NS16998 · United States
NIAID NIH HHS · K11 AI00610 · United States
External Links
PubMed source DOI: 10.1128/JVI.62.12.4594-4604.1988 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2